RxDoctor Payments Data

Nneka Meka, DPM

Podiatrist · New Orleans, LANPI 1588002240

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (54.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Mimedx Group, Inc. at 24.4% of the total. Reporting peaked in 2024 at $5,149 and has fallen 85.2% since, to $760 in 2025.

$9,058in general payments, 2019–2025

Across 120 payments — averaging $75.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$2K
  • Smith+Nephew$2K
  • Stryker$965
  • Endo USA, Inc.$963
  • Johnson & Johnson$840
  • Amniox Medical, Inc.$589
  • plus $2K from 13 others
$92,215in research payments, 2019–2025

Across 100 payments — averaging $922.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$92K

What the payments were for

  • Consulting fees$7809%
  • Travel & lodging$3,37137%
  • Food & beverage$4,90654%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,058 in reported general payments places this provider in the 85th percentile of 68 podiatrist providers in Louisiana.

See all podiatrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$34,891
Medicare patients
162
Services billed
440

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin Sulfate11$23,414
Methylprednisolone66$531
Tobramycin79$511
Diclofenac Sodium ErDiclofenac Sodium14$414
Doxycycline Hyclate45$364
Terbinafine Hcl17$230
Ciclopirox21$208
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$120
Ciprofloxacin Hcl11$94
Gabapentin26$83
Meloxicam34$72
Levofloxacin15$58

Paid to pharmacies, not to this prescriber.

Other podiatrist in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →